Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH ± Rituximab + JZP458 for Newly-Diagnosed Ph- B-ALL or T-ALL
NCT06738368Phase 2Suspended
- Sponsor
- University of Washington
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Asparaginase erwinia chrysanthemi in acute lymphoblastic leukemia (ALL), sponsored by University of Washington. Primary endpoint: Measurable residual disease negativity. Started May 2026; status: suspended.
02
Drugs
Asparaginase erwinia chrysanthemi
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06738368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738368.